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1. Introduction
Melanoma is the most aggressive form of skin cancer and accounts for 4% of all skin cancers
and nearly 75% of all melanoma deaths. According the National Cancer Institute, the incidence
of melanoma is increasing 6-7% annually. In 2012, it is estimated that there will be 76,250 new
cases of melanoma and more than 9,000 deaths. Risk factors for melanoma include one or more
severe sunburns, a familial history, excessive presence of moles, and fair skin. Melanoma is
unique from many cancers in that it that the tumor suppressor p53 is functional in a relatively
high percentage of tumors. Despite functional p53 protein, melanoma cells evade p53-
mediated apoptosis because of complex alterations in the apoptotic pathways. This chapter
will discuss the aberrant apoptosis mechanisms that exist in melanoma and provide insight
on to how these alterations could be therapeutically targeted.
2. P53
The tumor suppressor protein p53 has long been regarded as the guardian of the genome and
is mutated in more than half of all human cancers. The functional status of p53 is of significant
clinical importance because of its role in apoptosis, cell cycle arrest, and DNA repair; all cellular
processes targeted by chemotherapy and radiation therapy [1]. The human p53 gene is highly
conserved and consists of seven exons. The protein exists in a latent form and is activated
through tetramerization, allowing p53 to then bind with high affinity to DNA. The tetramer
conformation forms through interactions between regions in the C-terminus. Once activated,
p53 can recognize sequence specific binding sites on target genes and stimulate their activation.
p53 mutations are predominantly seen in the DNA binding domain, and very rarely occur in
the oligomerization region [2]. The half-life of p53 is short and is increased acutely in response
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to DNA damage or changes in oxidation status. Upon activation, p53 is phosphorylated at
various serine residues at the N or C terminus. The phoshorylation sites vary depending on
the type of damage inflicted on the cell. Once phosphorylated, p53 acts as a transcription factor,
translocating to the nucleus and binding to promoter elements of downstream target genes [3].
3. p53 and apoptosis
One of the essential roles of p53 is to maintain cellular integrity through transducing apoptosis,
programmed cell death, in the event of an irreparable damage to prevent propagation of this
aberrancy through uninterrupted proliferation. The mechanism of cell growth without checks
and balances is the essence of malignancy; making p53 central to the governing of cell growth.
Cellular damage caused by agents such as UV light, ionizing radiation, hypoxia, and oxidative
stress will lead to the activation of p53, allowing for p53-dependent apoptosis to occur. The
role of p53 in the mitochondrial apoptotic cascade is largely through its activities as a tran‐
scription factor for several pro-apoptotic proteins. p53 induced apoptosis can be activated via
intrinsic and the extrinsic cellular pathways [4;5].
3.1. Intrinsic apoptosis
The intrinsic or mitchondrial apoptotic cascade results from genotoxic stress such as UV
damage, oxidative stress, hypoxia, chemotherapy, or ionizing radiation. As depicted in Figure
1, activation of p53 from stress stimuli leads to activation of Bax and Bak. These proteins are
important players in apoptosis and are members of the Bcl-2 family, which is made up of both
pro and anti-apoptotic proteins. Family members are classified by structural similarity to the
Bcl-2 homology (BH) domains (BH1, BH2, BH3, and BH4), as well as a transmembrane domain.
The BH3 domain is referred to as the “death domain” and is the minimum requirement for the
protein to have pro-apoptotic functions. Once activated, pro-apoptotic Bax and Bak lead to
depoloarization of mitochondria and the release of cytochrome c, a small heme protein, which
is bound loosely within the mitochondrial membrane. The pro-apoptotic functions of Bax and
Bak are antagonized by the structurally similar anti-apoptotic proteins Bcl-2 and Bcl-xL. The
Bcl-2 family also contains ‘BH3 only’ proteins that are exclusively pro-apoptotic and include
Bax, PUMA, and Bid. Upon release, cytochrome c complexes with apoptosis protease activa‐
tion factor (APAF-1) to form an apoptosome. The apoptosome then binds to inactivated pro-
caspase 9, the initiating caspase. Once activated, caspase 9 goes on to cleave caspase 3, the
effector caspase responsible for executing apoptosis [6-8].
3.2. Extrinsic apoptosis
Extrinsic apoptosis involves death receptor activation through activation of the TNF-R family
proteins (Tumor necrosis factor receptor) including Fas, PERP, and DR5. The Fas receptor is
located on the cell surface and is activated by the ligand FasL, which is largely expressed by
T cells. Fas ligands, which usually exist as trimmers, bind and activate their receptors by
inducing receptor trimerization. Activated receptors recruit adaptor molecules such as Fas-
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associating protein with death domain (FADD), which then recruit procaspase 8 to the receptor
complex, where it undergoes autocatalytic activation. Activated caspase 8 activates caspase 3
through two pathways. In the more complex pathway caspase 8 activates Bcl-2 interacting
protein (Bid), which interacts with Bax to promote translocation of Bax to the inner mitochon‐
drial membrane where it triggers cytochrome c release. The released cytochrome c binds to
apoptotic protease activating factor-1 (Apaf-1). As in intrinsic apoptosis, the apoptosome leads
to activation of caspase 9, which is then able to cleave and activate procaspase 3, ultimately
leading to DNA fragmentation [8;9]. Figure 1 depicts the intersection of intrinisic and extrinsic
apoptosis and onset of extrinsic apoptosis through death receptor activation.
Figure 1. Intersecting intrinsic and extrinsic apoptotic pathways
4. Role of p53 in melanogenesis
4.1. Tyrosinase
The role of DNA damage and DNA repair in the stimulation of melanogenesis is corroborated
by the observation that activated p53 upregulates transcription of tyrosinase, the rate-limiting
enzyme involved in melanin production. Tyrosinase is a glycoprotein found in the melano‐
somal membrane. The protein has an inner melanosomal domain, which contains a catalytic
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region and a short transmembrane, and a cytoplasmic domain made up of about 30 amino
acids. Histidine residues present in the catalytic domain portion of tyrosinase bind copper ions
needed for tyrosinase activity. Structural studies of the tyrosinase promoter region have
revealed the presence of a TATA box, CAAT box, 5 AP-1 sites, 2 AP-2, 2 glucocorticoid
responsive elements, 2 UV responsive elements, and 3 Oct-1 sites [10]. The role of tyrosinase
in pigmentation reactions is the result of the oxidation of phenols.Tyrosinase hydroxylates
tyrosine in the first step of melanogenesis.Tyrosinase then catalyzes the hydroxylation of L-
tyrosinse to L-Dopa and its subsequent oxidation to dopaquinone. Dopaquinone then under‐
goes a series of reactions that lead to the synthesis of melanin within the melanocyte.
Tyrosinase has been studied as a prognostic marker of melanoma and has been useful in
staging the disease and determining prognosis [11;12]. Pathological analysis of melanoma
tissue samples have shown that tyrosinase detection is 97-100% specific to melanoma versus
other tumor types. Detection of tyrosinase mRNA in peripheral blood in patients with
metastatic melanoma using RT-PCR has been correlated to poor survival following immuno‐
therapy with IL-2 [12]. It has also been observed that patients with primary lesions do not show
tyrosinase mRNA in peripheral blood. Tyrosinase mRNA is not observed in peripheral blood
in patients with previous metastatic disease but who are currently disease free, implicating
that tyrosinase could be a useful prognostic tool [13].
Figure 2. Tyrosinase catalyzed reactions during melanogenesis
4.2. Melanogenesis
The activities of p53 as a tranducer of melanin production was further elucidated by Cui et al.
A p53 consensus sequence was discovered in the proopiomelanocortin (POMC) gene promot‐
er, establishing a line of communication between UV-induced DNA damage and the sun tan
response. The binding of p53 to the POMC promoter leads to an increase in the release of
POMC-derived alpha-melanocyte stimulating hormone (alpha-MSH), an important messen‐
ger inducing melanogenesis. Once released, alpha-MSH acts as a ligand for the melanocortin-1
receptor (MC1R), and binding results in the production of eumelanin [14]. Yamaguchi et al.
demonstrated that within keratinocytes, melanin acts as a native sunscreen. Melanin absorbs
UV light, thus protecting DNA from damage. In dark skin, which possesses higher levels of
melanin, protein levels of p53 are markedly lower following exposure to UV light compared
to more fair skin when p53 is highly stabilized following the same exposure. The photo
absorbent property of melanin protects from DNA damage, decreasing the activation of p53
[15]. Additionally, this observation supports that p53 is central to the UV damage response
through stimulation of melanogenesis as an innate means to protect skin from damage through
increased pigmentation.
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Figure 3. Role of p53 in transducing melanogenesis
5. p53 in melanoma
It has been observed that the frequency of p53 mutations in melanocytic tumors ranges from
5-25%, which is considerably lower than other types of cancers. Although mutations in p53
itself remain less frequent, the functional anti-tumor properties of p53 can be repressed by
many other mechanisms [16;17]. For example, p53 may be wildtype in melanoma but its
repressor, MDM2, is often overexpressed, causing p53 destabilization and a decreasing in its
transcriptional activities. Furthermore, the p53 upstream protein p14ARF is responsible for
the regulation of MDM2; once activated, p14ARF activates p53 through inhibition of MDM2,
allowing p53 to avoid proteosomal degradation and subsequent phosphorylation. Mutations
or a loss of p14ARF are frequently seen in melanoma [18]. Loss of function of one or both of
the p14ARF of p16INK4a proteins is thought to lead to a compensatory increase in p53 stability
as melanoma progresses [19].
In normal melanocytes, the apoptotic functions of p53 are attenuated in response to UV stress
in order to facilitate a longer cell life. One way this occurs is by upregulation of the p53
responsive gene GADD45a, which inhibits intrinsic apoptosis mediated through p53. It is
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speculated that this alteration in the apoptotic machinery that is specific to melanocytes could
be the genesis of the inherent chemoresistence of melanoma [20].
5.1. MDM2
The murine double minute protein (MDM2) functions as a negative regulator of p53. Its ability
to inhibit p53 is regulated by a negative feedback loop in which activated p53 leads to the
transcription and translation of MDM2, which then inhibits p53 [21]. Studies conducted in
mice have shown that MDM2 knockout mice are embryonic lethal in a p53-dependent manner,
where incessant p53 activity causes excessive apoptosis and ultimately death. A rescue effect
was observed by p53 knockout, confirming the role of MDM2 in p53 regulation [22]. MDM2
interacts with the transactivation domain of p53 via a p53-interacting domain on the N-
terminus of MDM2. This binding of MDM2 to p53 prevents p53 from binding to its transcrip‐
tional co-activators and subsequently prevents p53 from activating target genes [21]. In
melanoma, MDM2 has been found to be highly expressed in half of invasive primary and
metastatic melanomas. Amplification of the MDM2 locus is infrequent and over-expression is
the most common occurrence. In patient follow-up studies, decreased MDM2 expression was
associated with higher rates of survival. It has also been observed that both MDM2 and p53
are overexpressed in patients with melanoma [23]. This could be explained by the auto-
regulatory loop between p53 and MDM2. Increased expression of MDM2 is also possible due
to the loss of its repressor p14ARF, a common mutation or deletion seen in melanoma [24].
Without its repressor, MDM2 is constitutively active. This could account for the apoptotic
resistance observed in melanoma despite the largely wild-type status of p53.
5.2. INK4a/ARF locus
The INK4a/ARF locus contains the open reading frames of the proteins p16 INK4a and p14ARF.
This locus is of particular importance in melanoma because primary melanoma tumors and
nearly all melanoma cell lines carry a deletion at this locus [25]. Melanocytes have an intrins‐
ically longer life than many other cell types in the body. The anti-proliferative properties of
p53 may be attenuated in melanocytes to accommodate this longer cell life. All normal cells
have a finite number of cellular divisions. After this number is reached the cells enter a phase
called senescence, which is a protective cellular mechanism in cancer because it prevents
aberrant cell growth. Senescence can also be triggered through tumor suppressor proteins
when damage is sensed, minimizing uncontrolled cell growth and halting the path to malig‐
nancy [26]. The p16INK4a/Rb pathway as shown in Figure 4, is a key pathway for triggering
cellular senescence. The loss of this pathway in melanoma is thought to contribute to the
pathogenesis of melanoma. It is likely that loss of this protective cellular pathway is more
damaging than the potential loss of p53, offering an explanation as to why a p53 mutation is
not required for melanocytic tumorigenesis [26]. The p16INK4a protein works as a tumor
suppressor by binding to the cyclin-D-dependent protein kinases Cdk4 and Cdk6, preventing
them from phosphorylating Rb and preventing entrance into the cell cycle. The genes that
encode for both p16INK4a and Cdk4 have be identified as melanoma susceptibility genes [27].
The CdkN2A locus encodes p16INK4a as well as the tumor suppressor p14ARF. The p14ARF gene
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is encoded by a different promoter through the use of alternative reading frames. Both p14ARF
and p16INK4a share exons 2 and 3, while Exon 1B encodes p14 ARF and Exon 1A encodes for
p16INK4a. The two share no sequence homology and are not isoforms. The main regulatory
function of p14ARF is its binding to MDM2, which prevents the ubiquitination and subsequent
degradation of p53 [28]. In cases of familial melanoma, either p16INK4a or both p16INK4a and
p14ARF are mutated or deleted. It is rare to see mutations or deletions of p14ARF alone. Germline
mutations at the p16INK4a/p14ARF locus are observed in 20-40% of familial cases of melanoma
[25]. Somatic melanomas often involve mutations, deletions, or methylation of p16INK4a. Due
to a shared open reading frame, up to 40% of mutations or deletions that affect p16INK4a will
affect p14ARF [29]. Loss of homozygousity of the p16INK4a/p14ARF locus is observed in half of
sporadic melanomas and loss of p16INK4a and p14ARF expression occurs in 50-70% of invasive
melanomas [30].
Figure 4. Gene products from the INK4a/ARF locus
5.3. APAF-1
Apoptosis protease-activating factor-1 (APAF-1) is a regulator in the intrinsic apoptosis
pathway. When APAF-1 complexes with cytochome c a multimeric apoptosome is formed that
recruits and activates pro-caspase 9, the initiator of the mitochondrial apoptotic cascade. Once
activated, caspase 9 proceeds to activate pro-caspase 3 for the execution of apoptosis. A p53
transactivation site has been identified on APAF-1 determining that APAF-1 is a p53 respon‐
sive gene [31]. Downregulation of APAF-1 has been observed at the protein and mRNA level
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during melanoma progression, possibly contributing to the ability of melanoma to evade
apoptosis and thus conferring chemoresistance. Noncancerous melanocytes have normal
APAF-1 protein and mRNA levels. Conversely, loss of homozygousity has been detected in
42% of metastatic melanoma samples. Analysis of 19 metastatic lines revealed 10 lines with
low APAF-1 staining. Other studies have demonstrated significantly higher APAF-1 staining
in benign nevi compared with primary melanomas. Lower APAF-1 staining has also been
associated with greater tumor thickness in primary melanocytic tumors [32;33].
5.4. Bcl-2
The proapoptotic namesake for the Bcl-2 protein family has a complicated role in melanocytes
and in melanoma. Its proapoptotic role in melanocytes prevents premature cell death to allow
for continued production of pigment during the long life of the melanocyte. Bcl-2 knockout
studies in mice resulted in greying of the mice two weeks after birth due to melanocyte death.
The prognostic role of Bcl-2 in melanocytic tumors is controversial. Some analyses have shown
that melanoma primary tumors overexpressing Bcl-2 have an increased risk for invasion and
are responsible for drug resistance. It has also been observed that Bcl-2 levels actually decrease
in melanoma progression. Tumorigenic melanoma cells may take advantage of high endoge‐
nous Bcl-2 levels to survive under adverse environmental conditions that they may encounter
during metastatic transformation and chemotherapeutic intervention [5;34].
5.5. Bax
The protein Bcl-2 associated X protein (Bax) is a pro-apoptotic Bcl-2 family member highly
involved in the mitochondrial apoptotic cascade. It is a p53 target gene and in response to
stress, p53 will bind to the Bax promoter leading to its transcription, making it a valuable
indicator of p53 transcriptional activity as well as an indicator of intrinsic apoptosis. Bax will
translocate to the inner mitochondrial membrane, facilitating the depolarization and release
of cytochrome c. It has been observed that expression of Bax increases with melanoma
progression, although the tumors remain largely chemoresistant. This implicates that a ratio
effect is taking place; the inherent increase of Bcl-2 in melanocytes is potentially high enough
to negate the increased expression of Bax, thus facilitating tumor resistance to apoptosis. An
increase in Bax expression could also be a result of increased p53 stability and transcriptional
activity from mutation or deletion of proteins at the INK4a/ARF locus [35;36].
5.6. PUMA
The BH3-only mitchondrial protein p53 upregulated modulator of apoptosis (PUMA) belongs
to the Bcl-2 family of apoptotic regulators. The BH3 domain and its localization within the
mitochondria are necessary for PUMA to induce apoptosis or decrease cell growth. Studies have
not demonstrated that PUMA is post-translationally modified like other BH3 only proteins. In
response to stress stimuli, PUMA is transactivated by p53 [37]. Once activated, PUMA pro‐
motes the apoptotic pathway through inhibition of the anti-apoptotic protein Bcl-2, allowing
Bax and Bak to become activated and fosters cytochrome c release from the inner mitochondri‐
al membrane to signal initiation of apoptosis. The main pro-apoptotic effect of PUMA is such
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that once activated by p53, it will inhibit Bcl-2 anti-apoptotic family members in order to transduce
apoptosis [38]. It is possible that a loss of PUMA activity in melanoma cells could give rise to an
increase in Bcl-2 activity, leading to either evasion of apoptosis by therapy or propagating
transformation [39].  Complete silencing of PUMA in melanoma is not known. However,
immunostaining for PUMA in benign nevi have shown increased PUMA staining in compari‐
son to dysplastic nevi, primary melanoma, and metastatic tissues. When this data was com‐
pared to patient 5-year survival, patients exhibiting increased PUMA staining had a better
prognosis and therapeutic response compared to those with little or no PUMA staining [40].
5.7. p73
The p73 protein is a p53 homolog with tumor supressor activities, but it can also demonstrate
oncogenic properties, as the p73 gene can be transcribed into several different isoforms. The full
length p73 (TAp73) contains a N-terminal transactivation domain, proline rich region, DNA
binding domain, and C-terminal oligmerization domain. Members of the p53 family generally
carry approximately 70% sequence homology to p53, primarily in the DNA binding domain.
Homology in the DNA binding domain allows p73 to recognize and regulate p53 target genes.
Splice variants are generated through the use of an internal promoter, the use of an alternative
translation start site, or alternative splicing of the first exons. The splice variants have a truncat‐
ed N-terminus and do not contain a functional DNA binding domain, resulting in a dominant
negative protein with anti-apoptotic and growth promoting characteristics. These variants are
referred to as delta Np73. The delta isoforms possess antagonistic properties and counteract the
tumor supressor activities of TAp73.The intracellular concentration of the of the delta iso‐
forms in relation to the concentration of TAp73 is believed to be of significance. The ratio of the
delta isoforms to TAp73 levels may determine the role p73 plays in cell survival [41;42]. Loss or
mutation of the p73 gene have not been determined to be major events in the development in
melanoma. However, immunostaining of several of the Delta isoforms have shown increased
levels of delta isoforms in metastatic melanoma, in addition to strong p73 staining. This suggests
p73 may have a role as a positive regulator of tumor growth. In this situation, the ratio of the
delta isoforms to TAp73 may be of importance [43]. It is important to note that the delta isoforms
are markedly more stable in comparison to TA73, promoting the antagonistic effects. It has been
observed that MDM2 can disrupt p73 activities through interfering with the acetyl-transferase
p300/CBP. The interaction between p53 and p73 with MDM2 are similar in that they both interact
with the same hydrophobic pocket of MDM2, suggests that increased MDM2 activity may
decrease the actions of TAp73 as well as that of its isoforms [44].
6. p53-related targeted therapy
Targeting p53 pathways pharmacologically can serve as a very effective means of circum‐
venting chemoresistance observed in melanoma. The use of the small molecule inhibitor
nutlin-3 to inhibit MDM2 can restore the anti-tumor effects of p53. Due to the common loss of
p14ARF seen in melanoma and the compensatory increase in MDM2, p53 is unable to serve
as a mediator of chemosensitivity. The sequesteration of MDM2 in combination with temezo‐
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lomide potentiated the effects of the drug and increased sensitivity in vivo. The use of nutlin-3
to reinstate p53 function was also shown to be successful with the topoisomerase inhibitor
Topotecan [45]. It has also been suggested that the use of nutlin-3 could reverse inaction of p73
through MDM2 inactivation. Given the presence of antagonistic isoforms of p73, the presence
of MDM2 could potentially be a defect to exploit in melanoma in order to cease the anti-
apoptotic functions of the delta isoforms. Another possibility of therapeutic intervention is the
combination of p73 antissense in order to reduce the antagonistic effects of p73 while restoring
the native function of p53.
Along with the loss of the p16INK4a/p14ARF locus, an overexpression of cyclin D1 can occur in
melanoma, exacerbating the lack of the G1/S cell cycle checkpoint. Sauter et. al. demonstrated
that cyclin D1 antisense can work to sensitize melanoma cell lines to apoptosis. The intrinsic
increase of Bcl-2 in melanoma results in apoptotic resistance and a decrease in therapeutic
outcomes [46]. A study of 771 patients with advanced melanoma were treated with the Bcl-2
antisense Oblimersen in combination with Dacarbazine and had improved 24-month survival
and drug response, indicating a role of Bcl-2 in chemoresistence [47].
7. Conclusion
P53-mediated signaling in melanoma provides exceptional insight into the delicate signaling
interplay involved in melanoma progression. The role of p53 in the compensatory responses
to the infamous deletions and mutations associated with melanocytic tumors will further
elucidate mechanisms involved in tumor progression. Increased understanding of these
pathways will no doubt propel development of new treatment protocols forward, resulting in
new and more effective means to treat this very aggressive disease.
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